Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
复制标题
DOI：
10.1016/j.vaccine.2011.06.111
复制
发表时间：
2011-09-02
期刊：
影响因子：
5.5
通讯作者：
Smith, Gale
中科院分区：
文献类型：
--
作者：
Liu, Ye V.;Massare, Michael J.;Barnard, Dale L.;Kort, Thomas;Nathan, Margret;Wang, Lei;Smith, Gale
关键词：
sars冠状病毒是2003年全球大流行的原因，在8个月内感染了8000多人。目前还没有针对SARS的疫苗。我们开发了一种利用杆状病毒昆虫细胞表达系统生产高水平重组SARS病毒样颗粒（VLPs）疫苗的新方法，该疫苗含有SARS刺突(S)蛋白和流感M1蛋白。这些嵌合SARS VLPs具有与野生型SARS冠状病毒相似的大小和形态。我们在小鼠致死性攻毒模型中测试了纯化的嵌合SARS VLPs和全长SARS S蛋白疫苗的免疫原性和保护效果。SARS VLP疫苗含有0.8 μg的SARS S蛋白，在没有佐剂的情况下，通过肌肉注射（IM）或鼻内注射（IN）方式完全保护小鼠免于死亡。同样，含有4 μg无佐剂S蛋白的SARS VLP疫苗，将肺病毒滴度降低到可检测水平以下，保护小鼠免于体重减轻，并引发高水平的针对SARS冠状病毒的中和抗体。Sf9细胞产生的全长纯化SARS S蛋白也是一种有效的SARS- cov疫苗，但只有当IM与氢氧化铝共同给药时才有效。sars冠状病毒VLPs具有高度免疫原性，可诱导中和抗体，并提供抵抗致命挑战的保护。基于Sf9细胞的VLP疫苗是一种潜在的工具，可提供针对新型大流行病原体的保护。
SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.
登录
查看更多内容
DOI：
10.1016/j.ijantimicag.2010.06.016
发表时间：
2010-11
影响因子：
10.8
作者：
Anderson LJ;Tong S
通讯作者：
Tong S
影响因子：
3.7
作者：
Bright RA;Carter DM;Crevar CJ;Toapanta FR;Steckbeck JD;Cole KS;Kumar NM;Pushko P;Smith G;Tumpey TM;Ross TM
通讯作者：
Ross TM
影响因子：
64.8
作者：
Li W;Moore MJ;Vasilieva N;Sui J;Wong SK;Berne MA;Somasundaran M;Sullivan JL;Luzuriaga K;Greenough TC;Choe H;Farzan M
通讯作者：
Farzan M
影响因子：
5.5
作者：
Lokugamage KG;Yoshikawa-Iwata N;Ito N;Watts DM;Wyde PR;Wang N;Newman P;Kent Tseng CT;Peters CJ;Makino S
通讯作者：
Makino S
影响因子：
3.7
作者：
Bisht H;Roberts A;Vogel L;Subbarao K;Moss B
通讯作者：
Moss B